Financial reports
ARS
2023 FY
Annual report to shareholders
3 Apr 24
10-K
2023 FY
Annual report
15 Feb 24
10-Q
2023 Q3
Quarterly report
27 Oct 23
10-Q
2023 Q2
Quarterly report
28 Jul 23
10-Q
2023 Q1
Quarterly report
27 Apr 23
ARS
2022 FY
Annual report to shareholders
5 Apr 23
10-K
2022 FY
Annual report
16 Feb 23
10-Q
2022 Q3
Quarterly report
26 Oct 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
10-Q
2022 Q1
Quarterly report
27 Apr 22
Current reports
8-K
Results of Operations and Financial Condition
12 Apr 24
8-K
Departure of Directors or Certain Officers
22 Mar 24
8-K
Other Events
18 Mar 24
8-K
Regulation FD Disclosure
27 Feb 24
8-K
Other Events
8 Feb 24
8-K
Other Events
31 Jan 24
8-K
Material Modifications to Rights of Security Holders
30 Jan 24
8-K
Results of Operations and Financial Condition
19 Jan 24
8-K
Other Events
21 Nov 23
8-K
Regulation FD Disclosure
1 Nov 23
Registration and prospectus
25-NSE
Exchange delisting
15 Mar 24
424B2
Prospectus for primary offering
14 Mar 24
FWP
Free writing prospectus
13 Mar 24
424B5
Prospectus supplement for primary offering
13 Mar 24
424B2
Prospectus for primary offering
26 Jan 24
FWP
Free writing prospectus
24 Jan 24
424B5
Prospectus supplement for primary offering
24 Jan 24
424B2
Prospectus for primary offering
17 Nov 23
FWP
Free writing prospectus
16 Nov 23
FWP
Free writing prospectus
16 Nov 23
Proxies
DEFA14A
Additional proxy soliciting materials
3 Apr 24
DEF 14A
Definitive proxy
3 Apr 24
PX14A6G
Letter to shareholders
20 Apr 23
PX14A6G
Letter to shareholders
7 Apr 23
DEFA14A
Additional proxy soliciting materials
5 Apr 23
DEF 14A
Definitive proxy
5 Apr 23
PX14A6G
Letter to shareholders
7 Apr 22
DEFA14A
Additional proxy soliciting materials
6 Apr 22
DEF 14A
Definitive proxy
6 Apr 22
PX14A6G
Letter to shareholders
20 Apr 21
Other
EFFECT
Notice of effectiveness
1 Oct 20
CORRESP
Correspondence with SEC
28 Sep 20
CORRESP
Correspondence with SEC
28 Sep 20
UPLOAD
Letter from SEC
15 Sep 20
EFFECT
Notice of effectiveness
16 Jun 20
CORRESP
Correspondence with SEC
11 Jun 20
UPLOAD
Letter from SEC
8 Jun 20
EFFECT
Notice of effectiveness
20 Nov 17
CORRESP
Correspondence with SEC
16 Nov 17
UPLOAD
Letter from SEC
16 Nov 17
Ownership
SC 13G/A
bluebird bio, Inc.
10 Apr 24
SC 13G
C4 Therapeutics, Inc.
10 Apr 24
SC 13G/A
Replimune Group, Inc.
10 Apr 24
SC 13G
Biomea Fusion, Inc.
10 Apr 24
SC 13G/A
Altimmune, Inc.
10 Apr 24
SC 13G/A
Editas Medicine, Inc.
10 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
SC 13G/A
ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/
11 Mar 24
SC 13G/A
ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/
11 Mar 24
4
Eric W. Aboaf
4 Mar 24